Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783251 | 0.89 | P2RX7 (0.57) | MCHR1P2RX7POLBALDH1A1LMNA | |
| SCHEMBL3765922 | 0.88 | MCHR1 (0.52) | MCHR1P2RX7CNR2POLBALDH1A1 | |
| SCHEMBL3771851 | 0.85 | MCHR1 (0.48) | MCHR1P2RX7CNR2POLBALDH1A1 | |
| SCHEMBL713074 | 0.83 | P2RX7 (0.57) | MCHR1P2RX7POLB | |
| SCHEMBL15967383 | 0.83 | MCHR1 (0.45) | MCHR1P2RX7POLBHRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL711025 | 0.82 | MCHR1 (0.44) | MCHR1P2RX7POLBHRH3KCNH2 | |
| SCHEMBL3770678 | 0.79 | P2RX7 (0.60) | P2RX7 | |
| SCHEMBL3770883 | 0.77 | PRMT5 (0.38) | P2RX7CNR2HRH3KCNH2IDO1 | |
| SCHEMBL3783314 | 0.77 | SMN1; SMN2 (0.57) | MCHR1P2RX7POLBALDH1A1LMNA | |
| SCHEMBL30157440 | 0.76 | P2RX7 (0.67) | P2RX7POLBALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| EP-1869019-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | Pfizer Products Incorporated (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006106425-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | SLC1A2, SLC1A1, SLC6A5 | MCHR1 918/4885P2RX7 2105/4885CNR2 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.